Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 12/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18178309 | 0.94 | MRGPRX4 (0.42) | MRGPRX4LMNAKDM4ENPC1ALDH1A1 | |
| SCHEMBL18178308 | 0.92 | MRGPRX4 (0.41) | MRGPRX4LMNASMN1; SMN2SGMS2 | |
| SCHEMBL18178411 | 0.91 | MRGPRX4 (0.40) | MRGPRX4TRPV1LMNASLC22A12KDM4E | |
| SCHEMBL18182035 | 0.91 | MRGPRX4 (0.42) | MRGPRX4TRPV1SLC22A12SGMS2 | |
| SCHEMBL18178310 | 0.91 | MRGPRX4 (0.40) | MRGPRX4LMNAKDM4ENPC1ALDH1A1 | |
| SCHEMBL18178312 | 0.91 | MRGPRX4 (0.40) | MRGPRX4LMNAKDM4ENPC1ALDH1A1 | |
| SCHEMBL18178317 | 0.91 | KCNK3 (0.41) | MRGPRX4LMNAALDH1A1 | |
| SCHEMBL18178315 | 0.91 | MRGPRX4 (0.44) | MRGPRX4LMNAKDM4ENPC1ALDH1A1 | |
| SCHEMBL18178316 | 0.90 | MRGPRX4 (0.41) | MRGPRX4TRPV1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL18178679 | 0.89 | MRGPRX4 (0.39) | MRGPRX4TRPV1SLC22A12RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573904-B2 | Aromatic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | ZCCHC8, CBR3, CBX8 | MRGPRX4 167/4885TRPV1 765/4885LMNA 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.